Sanofi SA (SNY) is considered one of the best cheap stocks to buy for 2026. Citi Research initiated coverage, assigning Sanofi a Neutral rating and a €85 price target. Analysts expressed concerns about pipeline setbacks impacting long-term growth and stated that 2026 may be “catalyst-light” for Sanofi.

Citi mentioned that Sanofi has time to strengthen its pipeline over the next five years, but current valuation reflects setbacks. On January 23, Sanofi reported positive Phase 3 results for amlitelimab in treating atopic dermatitis. The experimental medicine showed promise and was well-tolerated in trials.

Sanofi SA (SNY) is a global healthcare company focusing on pharmaceutical products. While SNY shows investment potential, certain AI stocks may offer greater upside with less downside risk. For those seeking undervalued AI stock options, consider exploring the best short-term AI stock for opportunities.

Read more at Yahoo Finance: Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026